Evidence map›Paper›PMID 33946229›Full record

ArticleJournal of personalized medicine2021

The Usefulness of Cell-Based and Liquid-Based Urine Tests in Clarifying the Diagnosis and Monitoring the Course of Urothelial Carcinoma. Identification of Novel, Potentially Actionable,

Tadeusz Kałużewski, Grzegorz K Przybylski, Michał Bednarek, Sławomir Glazar, Magdalena Grabiec, Adam Jędrzejczyk, Łukasz Kępczyński, Izabela Kubiak, Dorota Kucharska, Agnieszka Morel and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tadeusz KałużewskiLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Grzegorz K PrzybylskiInstitute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Michał BednarekLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Sławomir GlazarDepartment of Pathomorphology, District Hospital, 98-220 Zdunska Wola, Poland.
Magdalena GrabiecLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.ORCID 0000-0001-7875-322X
Adam JędrzejczykDepartment of Urology, District Hospital, 97-500 Radomsko, Poland.
Łukasz KępczyńskiLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Izabela KubiakLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Dorota KucharskaLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Agnieszka MorelLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Magdalena OwczarekLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Marek RożnieckiLekarze Urolodzy Marek Rozniecki i Partnerzy, Non-public Department of Urology, 98-100 Lask, Poland.
Jordan SałamuniaLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Dominika SzewczykLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Jarosław SzwalskiCYTOPATH S.A., Histopathological Laboratory, 90-552 Lodz, Poland.
Bogdan KałużewskiLaboratory of Medical Genetics of the "Genos" Partnership-R&D Division, 91-033 Lodz, Poland.
Polish Mother’s Memorial Hospital Research Institute · PLInstitute of Human Genetics · PLRadom College · PL

Funding

European Regional Development Fund RPLD.01.02.01-10-0018/19 and RPLD.01.02.02-10-0130/19
6 · The paper itself

Abstract

Bladder cancer is one of the most common cancers in global statistics. One of the issues associated with this disease is the high incidence of cases with delayed diagnosis and what factors correlate with worse treatment outcomes. A possible reason for this may be the rather limited availability of non-invasive diagnostic tools. This short communication presents a case of a 68 year old male patient after an ineffective therapy, carried on for several years with symptoms commonly associated with prostate overgrowth that masked a carcinoma in situ of the urinary bladder. Implementation of several diagnostic techniques, including urine sediment cytology, immunocytochemistry, the fluorescence in situ hybridisation technique, the Bladder EpiCheck test and whole-genome sequencing, enabled the establishment of a correct diagnosis, implementation of appropriate treatment and provision of patient-friendly monitoring. The described case emphasises the usefulness of cell-based and liquid-based urine tests in bladder cancer diagnostic procedures.

Indexed as

bladder cancerBladder EpiCheckFISHnon-invasive urine testsurinary cytologyWGS, urinary carcinoma

Identifiers

PMID33946229
PMCPMC8145756
OpenAlexW3157136496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.